HomeCompareNURO vs PLD

NURO vs PLD: Dividend Comparison 2026

NURO yields 43.67% · PLD yields 3.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PLD wins by $5.63M in total portfolio value· pulled ahead in Year 8
10 years
NURO
NURO
● Live price
43.67%
Share price
$4.58
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$282.6K
Annual income
$51,335.69
Full NURO calculator →
PLD
PLD
● Live price
3.10%
Share price
$132.18
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.91M
Annual income
$4,750,725.19
Full PLD calculator →

Portfolio growth — NURO vs PLD

📍 PLD pulled ahead of the other in Year 8

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNUROPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NURO + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NURO pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NURO
Annual income on $10K today (after 15% tax)
$3,711.79/yr
After 10yr DRIP, annual income (after tax)
$43,635.34/yr
PLD
Annual income on $10K today (after 15% tax)
$263.66/yr
After 10yr DRIP, annual income (after tax)
$4,038,116.41/yr
At 15% tax rate, PLD beats the other by $3,994,481.08/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NURO + PLD for your $10,000?

NURO: 50%PLD: 50%
100% PLD50/50100% NURO
Portfolio after 10yr
$3.10M
Annual income
$2,401,030.43/yr
Blended yield
77.57%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

NURO
Analyst Ratings
2
Buy
Consensus: Buy
Altman Z
-14.9
Piotroski
1/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+2.9% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NURO buys
0
PLD buys
0
No recent congressional trades found for NURO or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNUROPLD
Forward yield43.67%3.10%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$282.6K$5.91M
Annual income after 10y$51,335.69$4,750,725.19
Total dividends collected$217.9K$5.78M
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: NURO vs PLD ($10,000, DRIP)

YearNURO PortfolioNURO Income/yrPLD PortfolioPLD Income/yrGap
1$15,067$4,366.81$11,241$540.96+$3.8KNURO
2$22,270$6,148.97$13,019$991.13+$9.3KNURO
3$32,324$8,494.27$15,801$1,870.97+$16.5KNURO
4$46,108$11,522.15$20,609$3,701.21+$25.5KNURO
5$64,697$15,360.67$29,919$7,867.97+$34.8KNURO
6$89,369$20,143.18$50,631$18,617.74+$38.7KNURO
7$121,629$26,004.42$105,528$51,352.20+$16.1KNURO
8← crossover$163,219$33,076.14$287,364$174,449.42$124.1KPLD
9$216,127$41,482.53$1,081,760$774,280.77$865.6KPLD
10$282,592$51,335.69$5,908,209$4,750,725.19$5.63MPLD

NURO vs PLD: Complete Analysis 2026

NUROStock

NeuroMetrix, Inc., a healthcare company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.

Full NURO Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this NURO vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NURO vs SCHDNURO vs JEPINURO vs ONURO vs KONURO vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.